Cover Image

Adverse Liver and Renal Outcomes After Initiating SGLT‐2i and GLP‐1RA Therapy Among Patients With Diabetes and MASLD

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Arunkumar Krishnan, Carolin V. Schneider, Diptasree Mukherjee, Tinsay A. Woreta, Saleh A. Alqahtani
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Journal of Diabetes
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA
by: Mengqing Zhang, et al.
Published: (2024)

Downstream Treatment Burden and Health‐Care Utilization Following Initiation of GLP ‐1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes
by: Yazan Alhamdan, et al.
Published: (2026)

Adherence to GLP1‐RA and SGLT2‐I affects clinical outcomes and costs in patients with type 2 diabetes
by: Stefano Ciardullo, et al.
Published: (2024)

Large‐Scale Plasma Proteomics Improves Prediction of Major Adverse Liver Outcomes in Individuals With MASLD
by: Hancheng Yu, et al.
Published: (2026)

Identifying Provider Prescribing Practices for GLP‐1RAs and SGLT‐2is in Patients With Type 2 Diabetes to Address Pharmacoinequity
by: Parnnate Wongsirisakul, et al.
Published: (2026)

Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes
by: Christine Ljungberg, et al.
Published: (2026)

Comparing SGLT2i and Other Oral Antidiabetic Drugs as Dual Therapy Add‐On to Metformin in Type 2 Diabetes: A Systematic Review and Meta‐Analysis
by: Yuhang Ma, et al.
Published: (2026)

Comparative effectiveness of combination therapy with SGLT ‐2 inhibitors and GLP ‐1 RAs compared with SGLT ‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study
by: Gregor A. Maier, et al.
Published: (2026)

Commentary on “Liver function effects of SGLT2 inhibitor and GLP ‐1 receptor agonist combination treatment in patients with type 2 diabetes ( post hoc analysis of RECAP study)”
by: Yu Zhang, et al.
Published: (2025)

Impact of Albuminuria and Renal Dysfunction on the Anemia‐Improving Effect of SGLT2 Inhibitors in Patients With Type 2 Diabetes: A Real‐World Observational Study
by: Ayami Kajiwara-Morita, et al.
Published: (2025)

Adherence to GLP ‐1 receptor agonists and SGLT2 inhibitors by out‐of‐pocket spending among Medicare beneficiaries with diabetes
by: Nicklas S. Klepser, et al.
Published: (2025)

One‐year usage patterns of SGLT ‐2 inhibitors and GLP ‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population
by: Louise A. Donnelly, et al.
Published: (2025)

Treatment of Youth‐Onset Type 2 Diabetes: Focus on SGLT‐2 Inhibitor Use
by: Silva Arslanian, et al.
Published: (2026)

Residual Gastric Content in Hospitalised GLP ‐ 1RA Users: Considerations for Interpretation
by: Jiajia Xia
Published: (2026)

The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes
by: Mario Luca Morieri, et al.
Published: (2026)

Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta‐analysis
by: Sama M. Abdel‐Rahman, et al.
Published: (2026)

The Impact of GLP ‐1‐Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta‐Analysis
by: Shih‐Ming Chuang, et al.
Published: (2026)

Machine Learning‐Based Risk Stratification for Metabolic Dysfunction Severity Among Diabetic Patients With Established MASLD: Distinguishing Normal‐Weight From Overweight Individuals
by: Yuelan Yin, et al.
Published: (2026)

Effectiveness of Saroglitazar in MASLD Patients: A Prospective, Real‐World Assessment of Liver and Metabolic Health
by: Mukulesh Gupta, et al.
Published: (2025)

Adding Finerenone to SGLT2 Inhibitors and Long‐Term Kidney Outcomes in Diabetic Kidney Disease
by: Masaru Matsui, et al.
Published: (2026)

Cardiorenal outcomes and mortality with GLP ‐1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: An updated systematic review and meta‐analysis
by: João Sérgio Neves, et al.
Published: (2025)

Effectiveness of add‐on therapy with SGLT2 inhibitors or GLP ‐1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study
by: Christina Baechle, et al.
Published: (2024)

Interpreting Pregnancy Risk After GLP ‐1 Receptor Agonists Discontinuation
by: Roberta Scairati, et al.
Published: (2026)

Concerns regarding “ GLP ‐ 1RA and the risk of non‐arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes”
by: Chien‐Hsiang Weng, et al.
Published: (2025)

Periodontal Disease: A Contributing Factor to Adverse Outcome in Diabetes
by: Edgard El Chaar
Published: (2025)

Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials
by: Yue Yin, et al.
Published: (2025)

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study
by: Kuo‐En Chen, et al.
Published: (2026)

Comparison of GLP‐1 Receptor Agonists, SGLT‐2 Inhibitors, and DPP‐4 Inhibitors as an Add‐On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review
by: Sanbao Chai, et al.
Published: (2024)

Methodological Concerns Regarding BMI Imbalance and Competing Risks in a Head‐to‐Head Comparison of SGLT2 Inhibitors and GLP ‐1 Receptor Agonists for Incident Dementia
by: Shio‐Shin Jean, et al.
Published: (2026)

Obesity and Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ): A Literature Review on Pathophysiology and Treatment
by: Michael Romanos, et al.
Published: (2026)

Early Postpartum Metabolic Heterogeneity Among Women Who Progressed to Type 2 Diabetes After Gestational Diabetes: A Prospective Cohort
by: Saifur R. Khan, et al.
Published: (2025)

Effect of SGLT2 Inhibitors + DPP‐4 Inhibitors on Urine Microbiota in Type 2 Diabetes
by: Marco Calvigioni, et al.
Published: (2026)

Baseline HbA1c and dementia risk at SGLT2i initiation in type 2 diabetes
by: Jiaqiang Zhang, et al.
Published: (2025)

Coexisting Asthma and Diabetes Are Associated With Adverse Metabolic and Inflammatory Profiles
by: Sixtus Aguree, et al.
Published: (2026)

Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset
by: Hannah Wallace, et al.
Published: (2025)

Incretin Hormone Levels (GLP‐1 and GIP) in Children and Adolescents With Type 1 Diabetes: A Systematic Review
by: Trine Witzner Hessel Lawaetz, et al.
Published: (2025)

The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk
by: Elias John Elenjickal, et al.
Published: (2026)

Beyond GLP ‐1
by: Zachary Bloomgarden
Published: (2026)

Fatty Liver Index as an Upstream Marker of Glycaemic and Cardiometabolic Dysregulation Preceding MASLD : Evidence From Two Longitudinal Cohorts
by: Hongmei Zhang, et al.
Published: (2026)

SGLT2 Inhibitors and the Risk of Infections in Type 2 Diabetes: Systematic Review and Meta‐Analyses of Real‐World Evidence
by: Maria J. Alfonso Arvez, et al.
Published: (2025)